What data are set to move the needle in gynecologic oncology care during #ESMO26? Experts break down some of the top abstracts to watch in Madrid #gynsm #ovca #oncology
Sign up and read more: www.onclive.com/view/long-te...
@onclive.bsky.social
@onclive.bsky.socialWhat data are set to move the needle in gynecologic oncology care during #ESMO26? Experts break down some of the top abstracts to watch in Madrid #gynsm #ovca #oncology
Sign up and read more: www.onclive.com/view/long-te...
@onclive.bsky.socialIn an ongoing phase 1 dose-escalation study evaluating the FSHR-directed CAR T-cell therapy lira-cel, the first case of stable disease has been reported in a patient with recurrent ovarian cancer #ovca #oncology
Read more on the ongoing study: www.onclive.com/view/fshr-di...
@onclive.bsky.social🇪🇺 The CHMP has has recommended EU marketing authorization for senaparib as a first-line maintenance treatment for advanced ovarian cancer, based on the phase 3 FLAMES trial.
Read more here 📈: www.onclive.com/view/eu-appr...
@onclive.bsky.social🇪🇺 The CHMP has has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer, based on the phase 3 ROSELLA trial.
Full details ➡️: onclive.com/view/chmp-re...
@onclive.bsky.social🗣️ OSE2101 Plus Pembrolizumab as Maintenance Boosts PFS in Platinum-Sensitive Ovarian Cancer
Read more here ➡️: www.onclive.com/view/ose2101...